Clinical Trial Update: RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography [Phase 4]

View source ↗

Summary

Phase 4 trial comparing renal toxicity of Visipaque (iodixanol) versus Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Insufficiency

Drugs mentioned

• Hexabrix (ioxaglate)
• VISIPAQUE (IODIXANOL)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Kidney Failure | Phase 4 | Status: COMPLETED